Trial
NCT00154427
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Acquired Bleeding Disorder
Intervention
activated recombinant human factor VII
Why stopped
Trial terminated after recruiting 172 patients but without proceeding to the highest dosing cohort as this no longer reflects common clinical practice
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-12